Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | FLT3 | P36888 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | DAO | P14920 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31081137 | 1.00 | KDM4E (0.72) | KDM4EALDH1A1GAAMAPK1NPC1 | |
| SCHEMBL29580477 | 0.84 | KDM4E (1.00) | KDM4EALDH1A1GAAMAPK1NPC1 | |
| SCHEMBL29354546 | 0.84 | KDM4E (0.70) | KDM4EALDH1A1GAAMAPK1NPC1 | |
| SCHEMBL474835 | 0.84 | KDM4E (1.00) | KDM4EALDH1A1GAAMAPK1NPC1 | |
| SCHEMBL1254745 | 0.84 | KDM4E (0.70) | KDM4EALDH1A1GAAMAPK1NPC1 | |
| SCHEMBL23331084 | 0.84 | FLT3 (0.70) | KDM4EALDH1A1GAAMAPK1NPC1 | |
| SCHEMBL4940211 | 0.82 | HDAC1 (0.68) | KDM4EALDH1A1GAAMAPK1HSD17B10 | |
| Methane SCHEMBL22343918 | 0.82 | FLT3 (0.96) | KDM4EALDH1A1GAAMAPK1NPC1 | |
| SCHEMBL5894386 | 0.82 | FLT3 (0.62) | KDM4EALDH1A1GAAMAPK1NPC1 | |
| Hydrochloric Acid SCHEMBL30164372 | 0.82 | KDM4E (0.68) | KDM4EALDH1A1GAAMAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111841896-B | Benzo-heterocycle hydroximic acid collecting agent and preparation method and application thereof | 武汉工程大学 | 2022-10-18 | — | — | CN | disclosed |
| CN-109096272-B | Indole hydroxamic acid compound with anti-tumor activity and application thereof | 沈阳药科大学 | 2021-04-02 | — | — | CN | disclosed |
| CN-109096272-B | Indole hydroxamic acid compound with anti-tumor activity and application thereof | 沈阳药科大学 | 2021-04-02 | — | — | CN | disclosed |
| CN-109096272-B | Indole hydroxamic acid compound with anti-tumor activity and application thereof | 沈阳药科大学 | 2021-04-02 | — | — | CN | disclosed |
| CN-111841896-A | Benzo-heterocycle hydroximic acid collecting agent and preparation method and application thereof | 武汉工程大学 | 2020-10-30 | — | — | CN | disclosed |
| CN-109096272-A | A kind of indoles hydroxamic acid compound with anti-tumor activity and its application | 沈阳药科大学 | 2018-12-28 | — | — | CN | disclosed |
| CN-109096272-A | A kind of indoles hydroxamic acid compound with anti-tumor activity and its application | 沈阳药科大学 | 2018-12-28 | — | — | CN | disclosed |
| CN-109096272-A | A kind of indoles hydroxamic acid compound with anti-tumor activity and its application | 沈阳药科大学 | 2018-12-28 | — | — | CN | disclosed |
| CN-104080451-B | Use of indole hydroxamic acids and indoline hydroxamic acids for the treatment of heart failure or nerve injury | 台北医学大学 | 2016-08-24 | — | — | CN | disclosed |
| CN-104080451-B | Use of indole hydroxamic acids and indoline hydroxamic acids for the treatment of heart failure or nerve injury | 台北医学大学 | 2016-08-24 | — | — | CN | disclosed |
| EP-1631567-A2 | HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-03-08 | — | — | EP | disclosed |
| CN-1630512-A | Pharmaceutical tablet | PHARMACIA CORP (US) | 2005-06-22 | — | — | CN | disclosed |
| WO-2005016918-A2 | HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20040186114-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-23 | — | — | US | disclosed |
| EP-0544819-B1 | INDOLE DERIVATIVES WHICH INHIBIT LEUKOTRIENE BIOSYNTHESIS | ABBOTT LAB (US) | 1995-12-06 | — | — | EP | disclosed |
| US-5459150-A | Treatment of allergies and inflammatory diseases | ABBOTT LABORATORIES (US) | 1995-10-17 | — | — | US | disclosed |
| EP-0544819-A4 | INDOLE DERIVATIVES WHICH INHIBIT LEUKOTRIENE BIOSYNTHESIS | — | 1993-10-20 | — | — | EP | disclosed |
| EP-0544819-A1 | INDOLE DERIVATIVES WHICH INHIBIT LEUKOTRIENE BIOSYNTHESIS. | ABBOTT LAB (US) | 1993-06-09 | — | — | EP | disclosed |
| US-5095031-A | Enzyme inhibitors, antiallergens, antiinflammatory | ABBOTT LABORATORIES (US) | 1992-03-10 | — | — | US | disclosed |
| WO-1992003132-A1 | INDOLE DERIVATIVES WHICH INHIBIT LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186114-A1 | Cytokine inhibitors | IL1A, IL1B, IL1R1 | KDM4E 3470/4885ALDH1A1 896/4885GAA 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.